Literature DB >> 10601608

Balloon-occluded arterial infusion chemotherapy, simple total hysterectomy, and radiotherapy as a useful combination-therapy for advanced cancer of the uterine cervix.

O Ishiko1, T Sumi, T Yasui, Y Matsumoto, N Kawamura, S Ogita, T Kamino, K Nakamura, R Yamada.   

Abstract

We first performed 3 or 4 courses of balloon-occluded arterial infusion (BOAI) chemotherapy in 19 patients with advanced cancer of uterine cervix classified as stage III-IV according to the International Federation of Gynecology and Obstetrics. In the patients in whom the first BOAI resulted in insufficient drug accumulation in tumor tissue, the ovarian arteries and veins were ligated to improve the therapeutic effect. Ultimately simple total hysterectomy and radiotherapy were performed in 9 patients in whom the uterus was resectable (the combination group), and radiotherapy alone was conducted in the other 10 patients in whom hysterectomy was not practicable (the incomplete group). The survival rates were significantly higher in the combination group (2-year survival 88. 9%; 5-year survival 66.7%) than in the incomplete group (p=0.0013).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10601608

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  UCP2 expression may represent a predictive marker of neoadjuvant chemotherapy effectiveness for locally advanced uterine cervical cancer.

Authors:  Kenji Imai; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Reiko Tasaka; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

2.  Expression of epidermal growth factor-like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Makoto Yamauchi; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Reiko Tasaka; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2016-10-25       Impact factor: 2.967

3.  Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Masatomo Teramae; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2014-09-24

4.  XPA expression is a predictive marker of the effectiveness of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Takuma Wada; Takeshi Fukuda; Masahiro Shimomura; Yuta Inoue; Masaru Kawanishi; Reiko Tasaka; Tomoyo Yasui; Kazuo Ikeda; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

5.  Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Masanari Morishita; Toshiyuki Sumi; Yusuke Nakano; Masatomo Teramae; Takeshi Fukuda; Hiroyuki Nobeyama; Hiroyuki Yoshida; Yoshinari Matsumoto; Tomoyo Yasui; Osamu Ishiko
Journal:  Exp Ther Med       Date:  2011-12-05       Impact factor: 2.447

6.  PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer.

Authors:  Masahiro Shimomura; Takeshi Fukuda; Yuichiro Awazu; Shigenori Nanno; Yuta Inoue; Hiroaki Matsubara; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2020-12-24       Impact factor: 2.967

7.  Fyn expression is associated with the response of patients with locally advanced uterine cervical squamous cell carcinoma to neoadjuvant chemotherapy.

Authors:  Shigenori Nanno; Takeshi Fukuda; Takuya Noda; Eijiro Uchikura; Yuichiro Awazu; Kenji Imai; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2022-08-11

8.  Malignant müllerian mixed tumor of the uterine cervix with a small cell neuroendocrine carcinoma component.

Authors:  Satoru Munakata; Emi Iwai; Tomohito Tanaka; Michihiko Nakamura; Takayoshi Kanda
Journal:  Case Rep Pathol       Date:  2013-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.